Glass House Brands (GLAS) Long-Term Investments (2020 - 2025)
Glass House Brands' (GLAS) quarterly Long-Term Investments came in at $172000.0 in Q2 2025, down 92.36% year-on-year from $2.3 million in Q2 2024, and down 92.78% on a QoQ basis from $2.4 million in Q1 2025.
Glass House Brands (GLAS) Long-Term Investments (2020 - 2025) Analysis & Trends
Glass House Brands (GLAS) has 6 years of Long-Term Investments data on file, last reported at $172000.0 in Q2 2025.
- On a quarterly basis, Long-Term Investments fell 92.36% year-over-year to $172000.0 in Q2 2025; TTM through Jun 2025 was $172000.0, a 92.36% decrease from a year earlier, with the FY2024 full-year figure at $2.3 million, up 0.6% from the prior year.
- Long-Term Investments for Q2 2025 stood at $172000.0, down from $2.4 million in the prior quarter.
- Over the last five years, Long-Term Investments for GLAS reached as high as $8.9 million in Q1 2021 and fell as low as $172000.0 in Q2 2025.
- Historically, Long-Term Investments has averaged $3.9 million across 5 years, with a median of $2.3 million in 2024.
- Across the five-year window, Long-Term Investments climbed 18.3% in 2024 and sank 92.36% in 2025, its largest moves.
- Year by year, Long-Term Investments stood at $7.2 million in 2021, then plunged by 41.0% to $4.2 million in 2022, then sank by 45.2% to $2.3 million in 2023, then climbed by 0.6% to $2.3 million in 2024, then tumbled by 92.65% to $172000.0 in 2025.
- Per Business Quant data, the three most recent Long-Term Investments figures were $172000.0 in Q2 2025, $2.4 million in Q1 2025, and $2.3 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 56.09 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 1.32 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 12.05 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 146.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 172,000.00 |
| Mar 31, 2025 | 2.38 Mn |
| Dec 31, 2024 | 2.34 Mn |
| Sep 30, 2024 | 2.30 Mn |
| Jun 30, 2024 | 2.25 Mn |
| Mar 31, 2024 | 2.35 Mn |
| Dec 31, 2023 | 2.33 Mn |
| Sep 30, 2023 | 2.11 Mn |
| Jun 30, 2023 | 2.02 Mn |
| Mar 31, 2023 | 1.98 Mn |
| Dec 31, 2022 | 4.25 Mn |
| Sep 30, 2022 | 4.49 Mn |
| Jun 30, 2022 | 6.87 Mn |
| Mar 31, 2022 | 6.94 Mn |
| Dec 31, 2021 | 7.20 Mn |
| Sep 30, 2021 | 8.16 Mn |
| Mar 31, 2021 | 8.94 Mn |
| Dec 31, 2020 | 10.70 Mn |